Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

USA - NASDAQ:EOLS - US30052C1071 - Common Stock

6.82 USD
-0.21 (-2.99%)
Last: 11/19/2025, 2:58:15 PM
Fundamental Rating

3

EOLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
EOLS had a negative operating cash flow in the past year.
In the past 5 years EOLS always reported negative net income.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -27.10%, EOLS perfoms like the industry average, outperforming 52.60% of the companies in the same industry.
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 66.63%, EOLS is in the better half of the industry, outperforming 74.48% of the companies in the same industry.
EOLS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EOLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EOLS has more shares outstanding
The debt/assets ratio for EOLS has been reduced compared to a year ago.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.80, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
EOLS has a Altman-Z score of -1.80. This is comparable to the rest of the industry: EOLS outperforms 46.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.8
ROIC/WACCN/A
WACC10.18%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.27 indicates that EOLS has no problem at all paying its short term obligations.
With a Current ratio value of 2.27, EOLS perfoms like the industry average, outperforming 40.63% of the companies in the same industry.
A Quick Ratio of 1.86 indicates that EOLS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.86, EOLS is in line with its industry, outperforming 42.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.86
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for EOLS have decreased by -9.76% in the last year.
EOLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.76%.
Measured over the past years, EOLS shows a very strong growth in Revenue. The Revenue has been growing by 50.14% on average per year.
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%

3.2 Future

Based on estimates for the next years, EOLS will show a very strong growth in Earnings Per Share. The EPS will grow by 62.01% on average per year.
Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 21.42% on average per year.
EPS Next Y-91.76%
EPS Next 2Y82.04%
EPS Next 3Y81.42%
EPS Next 5Y62.01%
Revenue Next Year11.18%
Revenue Next 2Y18.76%
Revenue Next 3Y22.78%
Revenue Next 5Y21.42%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EOLS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 20.76, the valuation of EOLS can be described as rather expensive.
76.04% of the companies in the same industry are more expensive than EOLS, based on the Price/Forward Earnings ratio.
EOLS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 35.39.
Industry RankSector Rank
PE N/A
Fwd PE 20.76
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as EOLS's earnings are expected to grow with 81.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.04%
EPS Next 3Y81.42%

More info and screens

0

5. Dividend

5.1 Amount

EOLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (11/19/2025, 2:58:15 PM)

6.82

-0.21 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners83.43%
Inst Owner Change-4.26%
Ins Owners7.31%
Ins Owner Change0.46%
Market Cap441.19M
Revenue(TTM)266.27M
Net Income(TTM)-61.99M
Analysts84.62
Price Target19.21 (181.67%)
Short Float %25.41%
Short Ratio9.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.87%
Min EPS beat(2)-108.79%
Max EPS beat(2)-0.95%
EPS beat(4)1
Avg EPS beat(4)-41.86%
Min EPS beat(4)-108.79%
Max EPS beat(4)3.2%
EPS beat(8)4
Avg EPS beat(8)-24.08%
EPS beat(12)8
Avg EPS beat(12)-14.96%
EPS beat(16)10
Avg EPS beat(16)-10.12%
Revenue beat(2)0
Avg Revenue beat(2)-12.02%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)-6.96%
Revenue beat(4)0
Avg Revenue beat(4)-7.33%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)-1.09%
Revenue beat(8)2
Avg Revenue beat(8)-2.45%
Revenue beat(12)4
Avg Revenue beat(12)-2.38%
Revenue beat(16)6
Avg Revenue beat(16)-1.12%
PT rev (1m)-2.35%
PT rev (3m)-18.12%
EPS NQ rev (1m)-9.52%
EPS NQ rev (3m)-7.81%
EPS NY rev (1m)2.59%
EPS NY rev (3m)-279.03%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)-0.67%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-15.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.76
P/S 1.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)0.33
Fwd EY4.82%
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS4.3
BVpS-0.29
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.63%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.75%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.86
Altman-Z -1.8
F-Score2
WACC10.18%
ROIC/WACCN/A
Cap/Depr(3y)67.26%
Cap/Depr(5y)52.74%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y-91.76%
EPS Next 2Y82.04%
EPS Next 3Y81.42%
EPS Next 5Y62.01%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%
Revenue Next Year11.18%
Revenue Next 2Y18.76%
Revenue Next 3Y22.78%
Revenue Next 5Y21.42%
EBIT growth 1Y-35.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-927.53%
EBIT Next 3Y291.62%
EBIT Next 5Y182.73%
FCF growth 1Y23.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.78%
OCF growth 3YN/A
OCF growth 5YN/A

EVOLUS INC / EOLS FAQ

What is the ChartMill fundamental rating of EVOLUS INC (EOLS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to EOLS.


Can you provide the valuation status for EVOLUS INC?

ChartMill assigns a valuation rating of 2 / 10 to EVOLUS INC (EOLS). This can be considered as Overvalued.


Can you provide the profitability details for EVOLUS INC?

EVOLUS INC (EOLS) has a profitability rating of 1 / 10.


How financially healthy is EVOLUS INC?

The financial health rating of EVOLUS INC (EOLS) is 3 / 10.


What is the expected EPS growth for EVOLUS INC (EOLS) stock?

The Earnings per Share (EPS) of EVOLUS INC (EOLS) is expected to decline by -91.76% in the next year.